Syncona Limited Issue of Shares Pursuant to the 2017 Dividend
15 August 2017 - 8:47PM
UK Regulatory
TIDMSYNC
15 August 2017
Syncona Limited
Issue of shares pursuant to the 2017 dividend
The Board of Syncona Limited (the "Company") today announces that a total of
1,564,683 new ordinary shares will be issued in satisfaction of the payment of
the Company's 2017 dividend to those qualifying shareholders who did not elect
to receive the dividend in cash. The new ordinary shares, when issued, will
rank pari passu with the existing issued ordinary shares of the Company.
Application has been made to the Financial Conduct Authority for the shares to
be admitted to the Official List, and to the London Stock Exchange for the
shares to be admitted to trading and it is expected that dealings will commence
in the new ordinary shares on 23 August 2017.
[ENDS]
Enquiries
Northern Trust International Fund Administration Services (Guernsey) Limited
Company Secretary
Tel: 01481 745001
Copies of this announcement and other corporate information can be found on the
company website at:www.synconaltd.com
About Syncona:
Syncona is a leading FTSE250 healthcare company focused on investing in and
building global leaders in life science. Our vision is to deliver
transformational treatments to patients in truly innovative areas of healthcare
while generating superior returns for shareholders. Our current investment
portfolio consists of seven high quality companies in life science and a
leading range of fund investments.
We seek to partner with the best, brightest and most ambitious minds in science
to build globally competitive businesses. We are established leaders in gene
therapy, cell therapy and advanced diagnostics, and focus on delivering
dramatic efficacy for patients in areas of high unmet need.
Our market leading funds portfolio seeks to generate superior returns by
investing in long only and alternative investment funds. This represents a
productively deployed evergreen funding base which enables us to take a long
term approach to investing in life sciences as we target the best new
opportunities and support our existing portfolio companies to grow and succeed.
Syncona is aligned with two of the premium charitable funders in UK science,
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both
of which are significant shareholders in our business. We make a donation of
0.3% of Net Asset Value to a range of charities each year.
END
(END) Dow Jones Newswires
August 15, 2017 06:47 ET (10:47 GMT)
Syncona (LSE:SYNC)
Historical Stock Chart
From Apr 2024 to May 2024
Syncona (LSE:SYNC)
Historical Stock Chart
From May 2023 to May 2024